Clinics, 2024 · DOI: https://doi.org/10.1016/j.clinsp.2024.100509 · Published: January 1, 2024
This study investigates the potential of stem cell therapy to improve motor function in mice with spinal cord injuries in the chronic phase. Mononuclear stem cells from human umbilical cord and placenta blood were implanted into mice at 3 and 6 weeks post-injury to assess nerve regeneration and motor recovery. The study focuses on the early chronic phase of spinal cord injury, a period where neuronal scar formation is not yet complete, offering a window for potential recovery. By using stem cells, the researchers aim to modulate the immune response, promote neurological recovery, and stimulate angiogenesis. The findings suggest that stem cell implantation in the chronic phase can indeed provide functional and histopathological benefits, with earlier intervention (3 weeks post-injury) yielding better results than later intervention (6 weeks post-injury). These results shed light on the potential therapeutic time window for stem cell therapy in chronic spinal cord injuries.
The study supports further investigation of stem cell therapy in human chronic spinal cord injury patients, particularly in the early chronic phase.
The results suggest that the timing of stem cell intervention is critical, with earlier treatment potentially leading to better outcomes.
The use of human umbilical cord and placenta blood as a readily available source of stem cells offers a practical advantage for clinical applications.